Effects of 125I seed implantation combined with TIPS in the treatment of intrahepatic cholangiocarcinoma complicated by main portal vein tumor thrombus and portal hypertension

Abstract

Abstract: Objective To investigate the clinical effect of ¹²⁵I seed implantation combined with transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of intrahepatic cholangiocarcinoma complicated by main portal vein tumor thrombus (MPVTT) and portal hypertension. Methods Seventy-eight patients with intrahepatic cholangiocarcinoma and MPVTT combined with portal hypertension were selected in this study from January 2016 to December 2018. They were divided into a control group and a test group with 39 cases each by random number method. The patients in the control group was treated with TIPS surgery, while the patients in the test group was treated with ¹²⁵I seed implantation in combination with TIPS surgery. The two groups of patients were compared for portal pressure before and after the treatment, the standard remission rate and total effective rate, the cumulative survival rate, cumulative restenosis rate of shunts, and symptom recurrence at 6 months, 12 months, and 24 months after surgery. Results After treatment, the portal pressure of the two groups of patients was significantly lower than those before treatment, and the portal pressure of the test group was significantly lower than that of the control group (P<0.05). The standard remission rate and total effective rate of the experimental group were significantly higher than those of the control group (P<0.05). At 6 months, 12 months, and 24 months after operation, the cumulative survival rate of the test group was significantly higher than that of the control group (P<0.05). At 6 months after operation, the cumulative restenosis rate and symptom recurrence rate of the test group were significantly lower than those of the control group (P<0.05). Conclusion ¹²⁵I seed implantation combined with TIPS may significantly reduce the portal pressure in patients with intrahepatic cholangiocarcinoma and MPVTT and portal hypertension, stabilize tumor thrombus in portal trunk, and prolong the survival time of patients.

Key words: ¹²⁵I seed implantation, Transjugular intrahepatic portosystemic shunt, Intrahepatic cholangiocarcinoma, Portal hypertension

LIU Nian, LIU Jing-wu. Effects of ¹²⁵I seed implantation combined with TIPS in the treatment of intrahepatic cholangiocarcinoma complicated by main portal vein tumor thrombus and portal hypertension[J]. Chinese Hepatolgy, 2021, 26(10): 1115-1118.

References

[1] 池小斌, 罗祥基. 肝内胆管细胞癌外科治疗的疗效相关因素研究. 实用癌症杂志, 2015, 30:1697-1700.
[2] Doescher J, Veit JA, Hoffmann TK. The 8th edition of the AJCC Cancer Staging Manual. HNO, 2017, 65:956-961.
[3] 顾方明, 周伟平. 肝内胆管癌影像学诊断. 中国实用外科杂志, 2020, 40:143-145.
[4] 曹飞, 刘鹏, 巩鹏. 肝内胆管细胞癌的诊治进展. 国际外科学杂志, 2020, 47:411-415.
[5] 丁智锋, 殷世武, 张国兵,等. Viatorr覆膜支架行TIPS术的临床疗效研究. 临床放射学杂志, 2018, 37:1566-1569.
[6] 徐小元, 丁惠国, 贾继东,等. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 临床肝胆病杂志, 2016,8:56-58.
[7] 姜琴, 汪名权, 张国兵,等. 经颈静脉肝内门体分流术联合食管胃底静脉曲张栓塞术治疗门静脉高压胃底静脉曲张出血的临床研究. 中华消化内镜杂志, 2016,9:173.
[8] 姚欣, 周昊, 汤善宏,等. 经颈静脉肝内门体分流术后支架功能障碍的原因分析及处理策略. 临床肝胆病杂志, 2019, 35:125-129.
[9] 张玥, 王涛, 岳振东,等. TIPS联合¹²⁵I粒子植入治疗肝癌门脉主干癌栓及合并症的效果. 介入放射学杂志, 2020, 29:89-95.
[10] 喻雄杰, 李艳丽, 雷金华,等. 肝动脉导管化疗栓塞联合¹²⁵I粒子植入治疗原发性肝癌的效果分析. 中国医药, 2017:77-81.
[11] Berzigotti A, Reig M, Abraldes J G, et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. Hepatology, 2015,7:1425-1426.
[12] 牟思玉, 辛洋, 李天翔,等. 肝细胞癌根治性切除术后复发伴门静脉癌栓危险因素分析. 中国实用外科杂志, 2019,11:85-86.
[13] 李威, 王黎洲, 杨学刚,等. 采用覆膜支架行经颈静脉肝内门体静脉分流术治疗原发性肝癌并门静脉高压46例疗效分析. 中华消化杂志, 2015, 10:367-370.
[14] 蒋丽, 韩东明, 胡鸿涛,等. ¹²⁵I粒子植入联合肝动脉化疗栓塞术预防原发性肝癌合并门静脉癌栓消化道出血. 中华放射学杂志, 2016, 50:784-788.
[15] 张国正, 郑家平, 邵国良,等. 肝细胞肝癌¹²⁵I粒子植入影响肿瘤局部控制临床研究. 介入放射学杂志, 2019,8:656-660.

Effects of ¹²⁵I seed implantation combined with TIPS in the treatment of intrahepatic cholangiocarcinoma complicated by main portal vein tumor thrombus and portal hypertension

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	HU Dou-dou, REN Wan-lei, QIU Sha, JIANG Xiang-jun. A comparison between two animal models of liver cirrhosis and portal hypertension [J]. Chinese Hepatolgy, 2021, 26(7): 732-736.
[2]	YU Rui, SUN Qian, SHI Qiang-wei, WANG Chun-feng, YAO Jian-ning, ZHANG Lian-feng. Sarcopenia may predict the occurrence of hepatic encephalopathy in patients with liver cirrhosis after transjugular intrahepatic portosystemic shunt [J]. Chinese Hepatolgy, 2021, 26(6): 602-605.
[3]	BAI Yan-feng, HE Ling-ling, WEI Hong-shan. An analysis of the possible causes of low liver stiffness measurement in patients with esophageal and gastric varices bleeding [J]. Chinese Hepatolgy, 2021, 26(5): 490-493.
[4]	SHAN Qin-xing, ZHANG Xiao-dong, WANG Xi. The application single energy imaging of energy spectrum computed tomography and metal artifact reduction algorithm in the angiography of patients with liver cirrhotic portal hypertension after transjugular intrahepatic portosystemic stent shunt treatment [J]. Chinese Hepatolgy, 2021, 26(5): 502-504.
[5]	WANG Qing-qing, PENG Yu-hui, TANG Yan-fang. Analysis of clinical and pathological features of idiopathic non-cirrhotic portal hypertension [J]. Chinese Hepatolgy, 2021, 26(3): 291-295.
[6]	ZUO Chen-yan, SUN Lian-qin, LIU Cheng, YANG Wei, CHENG Wen-fang. Analysis of the correlation between APRI and portal vein pressure in patients with liver cirrhosis [J]. Chinese Hepatolgy, 2021, 26(1): 41-43.
[7]	FANG Qi-lou, NI Jian-xun, FAN Hong-xing, JIN Ge. Efficacy and safety of TACE and nanoparticles in the treatment of portal hypertension in early-stage liver cancer [J]. Chinese Hepatolgy, 2021, 26(1): 51-54.
[8]	WANG Tao, LI Mu-song, HAN Qiu-ran, LI Cai-hong, SUN Jing-wei. Analysis of the incidence and prognosis of spontaneous portosystemic shunt in patients with cirrhosis [J]. Chinese Hepatolgy, 2020, 25(9): 948-951.
[9]	WANG Ning, LIN Fang-ming, LV Ming. The application value of TIPS combined with GCVE in the treatment of portal hypertension complicated with massive upper gastrointestinal hemorrhage [J]. Chinese Hepatolgy, 2020, 25(9): 952-954.
[10]	LI Yong-sheng, LIANG Xiao-feng, MA Yan. The role of advanced dynamic flow imaging in evaluating the stent patency of transjugular intrahepatic portosystemic shunt [J]. Chinese Hepatolgy, 2020, 25(8): 803-805.
[11]	NIU Teng-teng, ZHANG Gong-xian, CHEN Bao-hua, WANG Zhen. Study on the risk factors of hepatolithiasis developing intrahepatic cholangiocarcinoma [J]. Chinese Hepatolgy, 2020, 25(7): 705-708.
[12]	WANG Ming-feng, LI Guang-yao, JIA Li-meng, OU Yun-song. The influence of preventive anticoagulation timing on the risk of postoperative venous thrombosis in patients with hepatitis B cirrhosis, portal hypertension and hypersplenism [J]. Chinese Hepatolgy, 2020, 25(12): 1297-1299.
[13]	LV Zhong-jun, LI fu-kui, SHI ming-tao, LI hong-xiao. Different types of left portal shunts for extrahepatic portal hypertension in children [J]. Chinese Hepatolgy, 2019, 24(4): 373-376.
[14]	LV Yu-cui, HE Li-juan. Application of transient elastography in diagnosis of non-cirrhotic portal hypertension [J]. Chinese Hepatolgy, 2019, 24(11): 1237-1239.
[15]	ZHANG Zhen, WANG Meng-long, ZHANG Hai-tao, ZHANG Qi-kun, LIU Fu-quan. Risk factors for early portal venous system thrombosis after devascularization with splenectomy and portal hypertension in cirrhotic patients with portal hypertension and preventive effects of blood activating, anticoagulation and antiplatelet therapy [J]. Chinese Hepatolgy, 2019, 24(1): 24-27.